Solvias, a pharmaceutical testing and manufacturing firm, has bought Cergentis.
The acquisition bolsters Solvias’ platform of biologics and cell and gene therapy testing services.
Archie Cullen, CEO of Solvias, stated, “We are focused on ensuring the safety of new therapies in development. Cergentis is a cornerstone acquisition that expands our solutions supporting complex and emerging therapies. We will continue to pursue strategic acquisitions that add specialized capabilities to our offering and advance our goal of being a forerunner in our industry.”